跳至主要内容
临床试验/CTRI/2021/07/034990
CTRI/2021/07/034990尚未招募2 期

Primary Surgery versus Primary Chemoradiation for Oropharyngeal Cancer (SCOPe trial) â??A Phase II/III Integrated Design Randomized Control Trial. - SCOPe

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histopathology proven diagnosis of squamous cell carcinoma of the oropharynx, localized to the tonsil and /or lateralized tongue-base
  • 2. ECOG Performance Status <=2
  • 3. Age >=18 to 70 years
  • 4. Anesthetic fitness obtained for surgery under general anesthesia
  • 5. Resectable primary tumor with an anticipation of achieving resection free margins either by minimally invasive/open techniques
  • 6. Clinical stage III or IV, i.e. T1 T2 or T3 -T4 with N0-N3.
  • Nodal disease with extranodal extension on clinical examination/
  • imaging may be included at the surgeonâ??s discretion, if the nodal disease is deemed resectable by the operating surgeon
  • 7. HPV negative status determined by p16 status
  • 8. No distant metastases below the clavicles, based upon the following minimum
  • diagnostic workup:
  • a.History/physical examination by the physician
  • b.Imaging of the head and neck (Contrast enhanced MRI for local workup and Chest CT/PET-CT for distant metastatic workup)
  • 9. Patients with no contraindications to Cisplatin chemotherapy
  • and radiotherapy
  • 10. Adequate organ function
  • a. Hematological- Hb > 10 g/L, ANC >= 1.5 x 109/L, platelets >= 100 x 109/L.
  • b. Liver functions - bilirubin <= 2 x upper limit normal (ULN), AST/ALT/ALP <= 2.5 x ULN, S. albumin >= 30 g/L.
  • c.Renal function - Creatinine <= 1.5 ULN, Creatinine clearance > 50 mL/min.
  • 11. Women of child bearing age should have a negative pregnancy test at the time of randomization and should be willing to use adequate contraception during the treatment phase of the trial
  • 12. Patients who can be followed up and must be able to provide informed consent prior to study entry

排除标准

  • 1. Prior head and neck malignancy
  • 2. Prior invasive malignancy, unless disease free for a minimum of 3 years
  • 3. Prior chemotherapy for a different cancer administered
  • within 3 years prior to registration
  • 4. Patients who have received any neoadjuvant/ induction chemotherapy
  • 5. Prior radiotherapy to the region of the head and neck that would result in overlap of radiation therapy fields
  • 6. Unresectable primary or nodal disease involving the carotid vessels, prevertebral fascia or skull base
  • 7. Large soft palate involvement >1 cm 8. Deep extension into larynx,
  • pre-epiglottic space and deep invasion into extrinsic
  • muscles of tongue
  • 9. Calculated GFR < 50 cc/min
  • 10.Patients who have uncontrolled cardiac
  • co morbidity
  • a.QTc prolongation (a value of >450 milliseconds)
  • b.Ejection fraction below 50%
  • c.Presence of regional wallakinesia
  • 11. Presence of previous episode of thrombosis or embolism or presence of a prothrombotic condition in last 1 year
  • 12. Presence of severe malnutrition as defined by body mass index of below 16kg per m2 or presence of weight loss of greater than 20% in la
  • st 6 months
  • 13. Severe active comorbidities such as severe cardiac failure, severe pulmonary compromise, type 1or 2 diabetes mellitus (Hb1ac of > 8 mg/dl) severe and active infections or life expectancy less than 6 months
  • 14. Prior allergic reaction to cisplatin
  • 15. Radiographic evidence of retropharyngeal and/or level VI metastasis
  • 16. Patients on other investigational drugs within last 30 days

研究者

相似试验

Study of surgery verses study of chemotherapy and... | 临床试验